The warning in three documents
The US heading is “Acute Kidney Injury Due to Volume Depletion”, meaning sudden kidney damage caused by losing body fluid. Since approval there have been cases in people on semaglutide, some severe enough to need haemodialysis, most after nausea, vomiting or diarrhoea had led to dehydration. Prescribers are asked to monitor kidney function in people with reactions that could deplete fluids, especially at the start and while the dose is being raised. [1]
The Canadian monograph adds that reports included worsening of existing chronic kidney failure, that people with kidney impairment may be at greater risk, and that some events occurred in people without known kidney disease. [3] The EU product information says such dehydration can, in rare cases, lead to a deterioration of kidney function, and that semaglutide is not recommended in severe kidney impairment or end-stage kidney disease. [2] Novo Nordisk’s patient page repeats the US advice to drink fluids and report digestive symptoms that do not go away. [4]
What the trials recorded
Section 6.1 gives the kidney injury figures from the adult weight-reduction trials, alongside related findings: low blood pressure and fainting, some of which the label links to fluid loss, and urinary stones from the large cardiovascular trial. [1]
| Finding (trial and source) | Placebo | Wegovy® / semaglutide |
|---|---|---|
| Acute kidney injury, adult weight trials, US and Canada [1][3] | 4 people, 0.2 per 100 patient-years | 7 people, 0.4 per 100 patient-years |
| Low blood pressure reactions, adult weight trials [1] | 0.4% | 1.3% |
| Fainting, adult weight trials [1] | 0.2% | 0.8% |
| Urinary stones (urolithiasis), SELECT [1] | 0.8% | 1.2% |
| Serious kidney composite outcome, SELECT, about 3 years [5] | 2.2% | 1.8% |
Who was more at risk, and when
The US label names two risk factors. Kidney-related reactions on Wegovy® were more likely in adults with a history of kidney impairment (the trials included 65 people with moderate or severe impairment at the start), and they occurred more often during dose titration, the weeks when the dose is being stepped up. Some trial cases happened together with digestive reactions or dehydration, and two more people on Wegovy® in other trials had kidney injury with dehydration. [1]
The EU document adds that people with moderate kidney impairment may have more digestive effects on semaglutide, which compounds the risk. [2] The Medication Guide asks you to tell your provider before starting if you have or have had kidney problems. [1]
Where the fluid loss comes from
Digestive side effects are common: in adults on 2.4 mg, vomiting was reported by 24% and diarrhoea by 30%, and severe digestive reactions by 4.1% versus 0.9% on placebo (section 5.6). [1] Most happen during dose escalation, which is why the kidney and stomach warnings sit close together. The EU product information puts the median length of a vomiting episode at 2 days and diarrhoea at 3 days, [2] so a few days of poor intake is the window to watch.
Section 17 asks prescribers to tell patients about the risk of dehydration from digestive reactions, to advise precautions against fluid loss, and to explain which kidney warning signs to report, along with nausea, vomiting or diarrhoea that persists. [1]
Long-term kidney outcomes in SELECT
The short-term warning is about dehydration. Over the longer term, a pre-specified analysis of SELECT, which gave semaglutide 2.4 mg or placebo to more than 17,600 adults with overweight or obesity and heart disease but without diabetes, looked at a composite of serious kidney outcomes such as a large sustained drop in kidney function, kidney failure or heavy protein in the urine. It occurred in 1.8% on semaglutide and 2.2% on placebo (hazard ratio 0.78), and kidney function declined slightly less on semaglutide, more so in people who started with reduced function. [5]
That finding comes from a trial population without diabetes and is not a Wegovy® indication; it does not cancel the dehydration warning. The two simply describe different things: sudden injury from fluid loss, and slower changes over years. Section 12.3 reports no clinically significant difference in semaglutide blood levels in people with kidney impairment, [1] a statement about how the body handles the medicine rather than about dehydration risk.
Other causes of sudden kidney injury
- Dehydration from any cause, as well as burns, bleeding, serious illness or surgery that lowers blood pressure. [6]
- Some medicines, including anti-inflammatory painkillers (NSAIDs), certain antibiotics and blood pressure medicines, and contrast dye used in scans. [6] These are general causes, not Wegovy® interactions, but worth mentioning to your prescriber if you are also losing fluids.
- Kidney infections, a blocked urinary tract, blood clots in kidney vessels and autoimmune kidney disease. [6]
- MedlinePlus lists the signs of dehydration as thirst, a dry mouth, passing little or dark urine, headache and muscle cramps, with confusion, dizziness and a fast heartbeat in more severe cases. [7]
Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Passing very little or no urine, especially with vomiting or diarrhoea | Your provider urgently; emergency care if unwell | Emergency | MedlinePlus [6]; Canadian leaflet [3] |
| Swelling of the legs, ankles or feet, confusion or shortness of breath | Stop the medicine and get immediate medical help | Emergency | Canadian leaflet [3] |
| Severe stomach pain that will not go away, with or without vomiting | Stop Wegovy® and call your provider straight away | Emergency | Medication Guide [1] |
| Nausea, vomiting or diarrhoea that does not settle | Your prescriber promptly | Today | Medication Guide [1] |
| Feeling faint or dizzy, dark urine or strong thirst while unwell | Your prescriber the same day | Today | Wegovy® section 6.1 [1]; MedlinePlus [7] |
| A kidney condition, past or present, or regular use of anti-inflammatory painkillers | Tell your prescriber before starting | At your next appointment | Medication Guide [1]; MedlinePlus [6] |
